Lucid Psycheceuticals Overview
- Year Founded
-
2020
- Status
-
Acquired/Merged
- Employees
-
2
- Latest Deal Type
-
M&A
- Financing Rounds
-
1
Lucid Psycheceuticals General Information
Description
Developer of novel therapeutics intended to cure mental health disorders. The company offers specialty psychedelic pharmaceutical therapies to treat critical neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and multiple sclerosis along with depression, anxiety, dementia and similar other conditions, enabling patients to lead healthier lives.
Contact Information
Website
www.lucidpsycheceuticals.com(Operating Subsidiary)
Corporate Office
- 243 College Street
- Suite 101
- Toronto, Ontario M5R 1T5
- Canada
Corporate Office
- 243 College Street
- Suite 101
- Toronto, Ontario M5R 1T5
- Canada
Lucid Psycheceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Lucid Psycheceuticals Comparisons
Industry
Financing
Details
Lucid Psycheceuticals Competitors (45)
One of Lucid Psycheceuticals’s 45 competitors is ACADIA Pharmaceuticals, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| XWPharma | Venture Capital-Backed | Redwood City, CA | ||||
| Retrotope | Formerly VC-backed | Los Altos, CA | ||||
| NeuroNascent | Venture Capital-Backed | Clarksville, MD | ||||
| CervoMed | Formerly VC-backed | Boston, MA |
Lucid Psycheceuticals Patents
Lucid Psycheceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4788357-A1 | Peptidyl arginine deiminase (pad) inhibitors and methods of using the same | Pending | 02-Oct-2023 | ||
| WO-2025074194-A1 | Peptidyl arginine deiminase (pad) inhibitors and methods of using the same | Inactive | 02-Oct-2023 | ||
| US-20260294917-A1 | Ingestible formulations comprising methylliberine and one or more sugars and their use to treat the adverse effects of alcohol consumption | Pending | 24-Apr-2023 | ||
| WO-2024224285-A1 | Ingestible formulations comprising methylliberine and one or more sugars and their use to treat the adverse effects of alcohol consumption | Inactive | 24-Apr-2023 | A61P25/32 |
Lucid Psycheceuticals Signals
Lucid Psycheceuticals FAQs
-
When was Lucid Psycheceuticals founded?
Lucid Psycheceuticals was founded in 2020.
-
Where is Lucid Psycheceuticals headquartered?
Lucid Psycheceuticals is headquartered in Toronto, Canada.
-
What is the size of Lucid Psycheceuticals?
Lucid Psycheceuticals has 2 total employees.
-
What industry is Lucid Psycheceuticals in?
Lucid Psycheceuticals’s primary industry is Drug Discovery.
-
Is Lucid Psycheceuticals a private or public company?
Lucid Psycheceuticals is a Private company.
-
What is the current valuation of Lucid Psycheceuticals?
The current valuation of Lucid Psycheceuticals is .
-
What is Lucid Psycheceuticals’s current revenue?
The current revenue for Lucid Psycheceuticals is .
-
Who are Lucid Psycheceuticals’s competitors?
ACADIA Pharmaceuticals, XWPharma, Retrotope, NeuroNascent, and CervoMed are some of the 45 competitors of Lucid Psycheceuticals.
-
When was Lucid Psycheceuticals acquired?
Lucid Psycheceuticals was acquired on 21-Sep-2021.
-
Who acquired Lucid Psycheceuticals?
Lucid Psycheceuticals was acquired by Quantum BioPharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process